Onto Innovation Inc. (ONTO) Stock

Understand Onto Innovation Inc.: how it makes money

Onto Innovation designs, develops, manufactures, and supports process control tools and software for semiconductor manufacturing, including macro defect inspection, 2D and 3D optical metrology, lithography systems, and process control analytical software, sold to customers worldwide with standalone systems and support contracts.

Cashflow stability is supported by recurring support economics, highlighted by a 95% renewal rate for existing recurring support contracts, while new tool and software demand flows through volume purchase agreements and major revenue pools tied to Specialty Devices and Advanced Packaging and Advanced Nodes.

Business quality (Mixed): Clear operating drivers exist in recurring support renewal and volume purchase agreement visibility, and the latest quarter shows profitable margins (50.1% gross margin, 11.5% operating margin), but the data provided does not break out how much software and services is recurring versus transactional, and several KPIs point to exposure to customer process transitions and approval timing.

Valuation: At 151× earnings, ONTO trades 151% above the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

• Recurring support renewals are high: The renewal rate for existing recurring support contracts is 95%, which supports steadier customer spending patterns after tool deployments.
• Demand visibility through volume agreements: Volume Purchase Agreements Combined Value is 0.3 USD_B, which can provide some visibility into near term tool demand.
• Revenue is concentrated in major semiconductor process needs: Specialty Devices and Advanced Packaging (0.16 B) and Advanced Nodes (0.08 B) make up most of the latest quarter revenue, aligning Onto with key manufacturing process control categories.

Bear case

• Product and customer concentration risk: Most revenue comes from Specialty Devices and Advanced Packaging and Advanced Nodes, so any slowdown in those areas could pressure results.
• Customer process transitions add timing risk: A portion of revenue is tied to new research and development or pilot line investments (60%), which can create timing variability compared with more mature production ramps.
• Program and approval timing can delay shipments: Systems Awaiting Government Approval is 0.01 USD_B, indicating some revenue and delivery timing could be constrained by approvals.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• Thermo Fisher Scientific Inc. (TMO)
• Illumina, Inc. (ILMN)
• Trimble Inc. (TRMB)
• Revvity, Inc. (RVTY)
• Bio-Rad Laboratories, Inc. (BIO)
• Avantor, Inc. (AVTR)
• Bruker Corporation (BRKR)
• Mirion Technologies, Inc. (MIR)